254 related articles for article (PubMed ID: 33211142)
1. Prognostic value of LI-RADS category on gadoxetic acid-enhanced MRI and 18F-FDG PET-CT in patients with primary liver carcinomas.
Min JH; Kim SH; Hwang JA; Hyun SH; Ha SY; Choi SY; Kim SW; Kim HS
Eur Radiol; 2021 Jun; 31(6):3649-3660. PubMed ID: 33211142
[TBL] [Abstract][Full Text] [Related]
2. Radio-pathologic correlation of biphenotypic primary liver cancer (combined hepatocellular cholangiocarcinoma): changes in the 2019 WHO classification and impact on LI-RADS classification at liver MRI.
Choi SH; Jeon SK; Lee SS; Lee JM; Hur BY; Kang HJ; Kim H; Park Y
Eur Radiol; 2021 Dec; 31(12):9479-9488. PubMed ID: 34037829
[TBL] [Abstract][Full Text] [Related]
3. Proliferative hepatocellular carcinomas in cirrhosis: patient outcomes of LI-RADS category 4/5 and category M.
Heo S; Kang HJ; Choi SH; Kim S; Yoo Y; Choi WM; Kim SY; Lee SS
Eur Radiol; 2024 May; 34(5):2974-2985. PubMed ID: 37848775
[TBL] [Abstract][Full Text] [Related]
4. LI-RADS Classification and Prognosis of Primary Liver Cancers at Gadoxetic Acid-enhanced MRI.
Choi SH; Lee SS; Park SH; Kim KM; Yu E; Park Y; Shin YM; Lee MG
Radiology; 2019 Feb; 290(2):388-397. PubMed ID: 30422088
[TBL] [Abstract][Full Text] [Related]
5. Prognosis after Curative Resection of Single Hepatocellular Carcinoma with A Focus on LI-RADS Targetoid Appearance on Preoperative Gadoxetic Acid-Enhanced MRI.
Moon JY; Min JH; Kim YK; Cha D; Hwang JA; Ko SE; Choi SY; Yun EJ; Kim SW; Won HJ
Korean J Radiol; 2021 Nov; 22(11):1786-1796. PubMed ID: 34402243
[TBL] [Abstract][Full Text] [Related]
6. LI-RADS M (LR-M) criteria and reporting algorithm of v2018: diagnostic values in the assessment of primary liver cancers on gadoxetic acid-enhanced MRI.
Kim MY; Joo I; Kang HJ; Bae JS; Jeon SK; Lee JM
Abdom Radiol (NY); 2020 Aug; 45(8):2440-2448. PubMed ID: 32382817
[TBL] [Abstract][Full Text] [Related]
7. Combined Hepatocellular-Cholangiocarcinoma: Magnetic Resonance Imaging Features and Prognosis According to Risk Factors for Hepatocellular Carcinoma.
Kim DH; Choi SH; Kim DW; Lee SS; Lim YS; Kim SY; Kim HJ; Kim JH; Byun JH
J Magn Reson Imaging; 2021 Jun; 53(6):1803-1812. PubMed ID: 33565208
[TBL] [Abstract][Full Text] [Related]
8. LI-RADS Category on MRI Is Associated With Recurrence of Intrahepatic Cholangiocarcinoma After Surgery: A Multicenter Study.
Hwang JA; Lee S; Lee JE; Yoon J; Choi SY; Shin J
J Magn Reson Imaging; 2023 Mar; 57(3):930-938. PubMed ID: 35833798
[TBL] [Abstract][Full Text] [Related]
9. Combined hepatocellular-cholangiocarcinoma: can we use contrast-enhanced ultrasound Liver Imaging Reporting and Data System (LI-RADS) to predict the patient's survival?
Yang J; Huang JY; Chen X; Ling WW; Luo Y; Shi YJ; Liu JB; Lu Q; Lyshchik A
Eur Radiol; 2021 Aug; 31(8):6397-6405. PubMed ID: 33492470
[TBL] [Abstract][Full Text] [Related]
10. LI-RADS category is associated with treatment outcomes of small single HCC: surgical resection vs. radiofrequency ablation.
Min JH; Lee MW; Rhim H; Han S; Song KD; Kang TW; Jeong WK; Cha DI; Kim JM; Choi GS; Kim K
Eur Radiol; 2024 Jan; 34(1):525-537. PubMed ID: 37526668
[TBL] [Abstract][Full Text] [Related]
11. Combined hepatocellular cholangiocarcinoma: LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acid-enhanced MR imaging.
Jeon SK; Joo I; Lee DH; Lee SM; Kang HJ; Lee KB; Lee JM
Eur Radiol; 2019 Jan; 29(1):373-382. PubMed ID: 29955948
[TBL] [Abstract][Full Text] [Related]
12. Risk stratification of LI-RADS M and LI-RADS 4/5 combined hepatocellular cholangiocarcinoma: prognostic values of MR imaging features and clinicopathological factors.
Wang Y; Zhu GQ; Zhou CW; Li N; Yang C; Zeng MS
Eur Radiol; 2022 Aug; 32(8):5166-5178. PubMed ID: 35316365
[TBL] [Abstract][Full Text] [Related]
13. Assessment of primary liver carcinomas other than hepatocellular carcinoma (HCC) with LI-RADS v2018: comparison of the LI-RADS target population to patients without LI-RADS-defined HCC risk factors.
Fraum TJ; Cannella R; Ludwig DR; Tsai R; Naeem M; LeBlanc M; Salter A; Tsung A; Shetty AS; Borhani AA; Furlan A; Fowler KJ
Eur Radiol; 2020 Feb; 30(2):996-1007. PubMed ID: 31654212
[TBL] [Abstract][Full Text] [Related]
14. Comparison of gadoxetic acid versus gadopentetate dimeglumine for the detection of hepatocellular carcinoma at 1.5 T using the liver imaging reporting and data system (LI-RADS v.2017).
Ding Y; Rao SX; Wang WT; Chen CZ; Li RC; Zeng M
Cancer Imaging; 2018 Dec; 18(1):48. PubMed ID: 30526674
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic accuracy of liver imaging reporting and data system (LI-RADS) v2014 for intrahepatic mass-forming cholangiocarcinomas in patients with chronic liver disease on gadoxetic acid-enhanced MRI.
Joo I; Lee JM; Lee SM; Lee JS; Park JY; Han JK
J Magn Reson Imaging; 2016 Nov; 44(5):1330-1338. PubMed ID: 27087012
[TBL] [Abstract][Full Text] [Related]
16. Targetoid hepatic observations on gadoxetic acid-enhanced MRI using LI-RADS version 2018: emphasis on hepatocellular carcinomas assigned to the LR-M category.
Park HJ; Kim YK; Cha DI; Ko SE; Kim S; Lee ES; Ahn S
Clin Radiol; 2020 Jun; 75(6):478.e13-478.e23. PubMed ID: 32033745
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of LI-RADS category on MRI in patients with primary hepatic lymphoepithelioma-like carcinoma.
Pan YJ; Liu W; Qiu QX; Miao SL; Zeng MS; Shan Y; Lin J; Xu PJ
Eur Radiol; 2023 Sep; 33(9):5993-6000. PubMed ID: 37014407
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors of gadoxetic acid-enhanced MRI for postsurgical outcomes in multicentric hepatocellular carcinoma.
Kim SS; Lee S; Kim MJ
Eur Radiol; 2021 May; 31(5):3405-3416. PubMed ID: 33146795
[TBL] [Abstract][Full Text] [Related]
19. Comparing Survival Outcomes of Patients With LI-RADS-M Hepatocellular Carcinomas and Intrahepatic Cholangiocarcinomas.
Kierans AS; Lafata KJ; Ludwig DR; Burke LMB; Chernyak V; Fowler KJ; Fraum TJ; McGinty KA; McInnes MDF; Mendiratta-Lala M; Cunha GM; Allen BC; Hecht EM; Jaffe TA; Kalisz KR; Ranathunga DS; Wildman-Tobriner B; Cardona DM; Aslam A; Gaur S; Bashir MR
J Magn Reson Imaging; 2023 Jan; 57(1):308-317. PubMed ID: 35512243
[TBL] [Abstract][Full Text] [Related]
20. Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy?
Zhang T; Huang ZX; Wei Y; Jiang HY; Chen J; Liu XJ; Cao LK; Duan T; He XP; Xia CC; Song B
World J Gastroenterol; 2019 Feb; 25(5):622-631. PubMed ID: 30774276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]